Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2025 19:40 ET | Source: Curium US LLC

Curium Finaliza a Aquisição da Monrol como Parte do seu Plano para Expandir Significativamente a Capacidade de Lutécio-177 e Pegada PET

Aquisição posiciona a Curium como principal fabricante do isótopo Lu-177Oferece experiência inovadora em P&D e pipeline para a CuriumAprimora a cobertura geográfica e a cadeia de suprimentos SPECT...
March 28, 2025 19:40 ET | Source: Curium US LLC

Curium Menyelesaikan Akuisisi Monrol sebagai Bagian dari Rencananya untuk Secara Signifikan Meningkatkan Kapasitas Lutetium-177 dan Jaringan PET

Menempatkan Curium sebagai produsen terkemuka isotop Lu-177Memberikan keahlian Litbang dan rangkaian tahap pengembangan produk (pipeline) yang inovatif ke CuriumMeningkatkan jangkauan geografis dan...
March 28, 2025 19:40 ET | Source: Curium

Curium schließt Übernahme von Monrol im Rahmen seines Plans zur erheblichen Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im Bereich der Positronen-Emissions-Tomographie (PET) ab

Dies positioniert Curium als führenden Hersteller des Isotops Lu-177Integration innovativer F&E-Expertise und Pipeline für CuriumVerbesserung der geografischen Abdeckung und Lieferkette von Curium...
March 28, 2025 02:00 ET | Source: Curium

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium
January 30, 2025 07:22 ET | Source: Curium

Curium Expands European Supply of Iodine-131 Diagnostic Capsules with New Partnership Agreement with Izotop

Curium announced today that it has expanded its existing partnership with Institute of Isotopes Co. Ltd. (Izotop).
January 28, 2025 04:24 ET | Source: Curium

Curium Further Expands European Availability of PYLCLARI – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients with Prostate Cancer

Curium announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer.
November 19, 2024 03:30 ET | Source: Curium

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial

ST. LOUIS, Mo., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that it has completed enrollment of its Phase 3 SOLAR-RECUR clinical trial. The trial is a...
November 13, 2024 10:57 ET | Source: Curium

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer

ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center,...
October 02, 2024 11:01 ET | Source: Curium US LLC

Curium ประกาศความร่วมมือเชิงกลยุทธ์กับ PeptiDream สำหรับผลิตภัณฑ์รักษามะเร็งต่อมลูกหมากในญี่ปุ่น

โดยเป็นความร่วมมือเพื่อพัฒนาทางคลินิก การยื่นเรื่องต่อหน่วยงานกำกับดูแล และการนำ 177Lu-PSMA-I&T และ 64Cu-PSMA-I&T...
October 02, 2024 11:01 ET | Source: Curium US LLC

Curium מכריזה על שותפות אסטרטגית עם PeptiDream לטיפול ממוקד מטרה בסרטן הערמונית ביפן

*שיתוף פעולה שיכלול פיתוח קליני, הגשה רגולטורית ומסחור ביפן של 177Lu-PSMA-I&T ו- 64Cu-PSMA-I&T *מתבסס על מערכת יחסים ארוכת שנים בין שתי החברות *ביפן מאובחנים מדי שנה כ-90,000 מקרים חדשים...